鎝－99m在放射藥物學的研究

Study on Technetium-99m in Radiopharmaceuticals

丁慧枝(Hueisch-Jy Ding) ； 楊朝欽(Chao-Chin Yang)

《The Kaohsiung Journal of Medical Sciences》 12卷3期 (1996/03) Pp. 132-144

https://doi.org/10.6452/KJMS.199603.0132

摘要

鎝的研究領域是特別具有挑戰性的，因為它是一個新的元素它的化學特性並未達一世紀之琢磨。然而由於鎝的發現使得核子醫學在功能性診斷上佔有舉足輕重的角色。未來鎝-99m在核子醫學臨床上的應用將並行於鎝化學在有機化學、分析化學、醫學化學及生物化學的發展。同時，新的、有實用性的鎝-99放射藥物將在世界各地繼續研究發展。在有機化學界對於鎝-99m錯化合物之螫合劑結構的設計與合成或修正之研究提供在體內新的生物性質。在分析化學界對鎝-99m標幟之放射藥物之結構特性進行純度分析鑑定的研究。醫學界則有興趣於鎝-99m錯化合物醫簡易結構特性化及與生物活性關係的研究。由近十年來的國際研討會發現關於鎝-99m錯化合物的化學結構與生物化學作用機制是以穩定鎝-99m參與靈敏的生物分子之反應進行研究，以達成製造有用的臨床製劑。生物化學上鎝-99ｍ臨床製劑牽涉到雙官能螫合劑(BCA: Bifunctional Chelating Agent)的各種標幟手段之發展似乎仍在成長中。至於發展鎝-99放射藥物學於酵解物利用性之研究及特異性生物學之定位應視為優先考慮。展望鎝-99m放射藥物化學新的成就，可能就在不久的未來研究報告中。

並列摘要

The technetium field involving a new element of which chemistry has not been honed in the research during the century is particularly challenging, it is exciting and satisfying to see the successful developement of a radiopharmaceutical agent which gives the clinical doctor new tools with which to assess function and in vivo biochemistry in nuclear medicine. The clinical application of technetium in nuclear medicine will parallel with the development of technetium chemistry in organic-analytical-medical- and biochemistry, and it is likely that useful new Tc-99m radiopharmaceuticals will rapidly make world-wide progress in the future years. The design and synthetic modifications of ligand structure in organic chemistry will impart new biological properties to the technetium complexes. A structure characterization Tc-99m labelled radiopharmaceuticals is highly desirable in analytical chemistry. We take much interest in the structural characterization of Tc-99m complexes stems to establish a structure/ in vivo activity relationship in medical chemistrv. The current clinical trend is to use Tc-99 radiopharmaceuticals with Tc-99m ”carrier-added” experiments for studies of chemical structure and biochemical mechanism of action. Technical diffculties in the various labeling approaches to these bifunctional chelating agents (BCA) which seem promising are often encountered during the ached procedures. High priority is given to development of Tc-99 m radiopharmaceuticals for studies of substrateutilization and localization of specific biological recognition sites. New accomplishments in technetium radiopharmaceutical are likely to be reported in the near future.

並列關鍵字

technetium-99m ； radiopharmaceuticals